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ABSTRACT 
 
 
Cardiovascular diseases, which presently are considered inflammatory diseases, affect 
millions of people worldwide. Chronic infections may contribute to the systemic 
inflammation suggested to increase the risk for cardiovascular diseases. Such chronic 
infections are periodontitis and Chlamydia pneumoniae infection. They are highly prevalent 
as approximately 10% of adult population and 30% of people over 50 years old are affected 
by severe periodontitis and 70-80% of elderly people are seropositive for C. pneumoniae. 
 
Our general aim was to investigate the role of infection and inflammation in atherosclerosis 
both in animal and human studies. We aimed to determine how the two pathogens alter the 
atherosclerosis-associated parameters, and how they affect the liver inflammation and lipid 
composition. Furthermore, we evaluated the association between matrix metalloproteinase-8 
(MMP-8), a proteinase playing a major role in inflammation, and the future cardiovascular 
diseases (CVD) events in a population-based cohort. 
 
For the animal experiments, we used atherosclerosis-susceptible apolipoprotein E deficient 
(apoE-/-) mice. They were kept in germ free conditions and fed with a normal chow diet. The 
bacteria were administered either intravenously (A. actinomycetemcomitans) or intranasally 
(C. pneumoniae). Several factors were determined from serum as well as from aortic and 
hepatic tissues. We also determined how cholesterol efflux, a major event in the removal of 
excess cholesterol from the tissues, and endothelial function were affected by these 
pathogens. In the human study, serum MMP-8 and its tissue inhibitor (TIMP-1) 
concentrations were measured and their associations during the follow-up time of 10 years 
with CVD events were determined. 
 
An infection with A. actinomycetemcomitans increased concentrations of inflammatory 
mediators, MMP production, and cholesterol deposit in macrophages, decreased lipoprotein 
particle size, and induced liver inflammation. C. pneumoniae infection also elicited an 
inflammatory response and endothelial dysfunction, as well as induced liver inflammation, 
microvesicular appearance and altered fatty acid profile. In the population-based cohort, men 
with increased serum MMP-8 concentration together with subclinical atherosclerosis (carotid 
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artery intima media thickness > 1mm) had a three-fold increased risk for CVD death during 
the follow-up.  
 
The results show that infections with A. actinomycetemcomitans and C. pneumoniae induce 
proatherogenic changes, as well as affect the liver. These data therefore support the concept 
that common infections have systemic effects and could be considered as cardiovascular risk 
factors. Furthermore, our data indicate that, as an independent predictor of fatal CVD event, 
serum MMP-8 could have a clinical significance in diagnosing cardiovascular diseases.  
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1. REVIEW OF THE LITERATURE 
 
1.1. Atherosclerosis and inflammation 
 
1.1.1. Introduction 
 
Cardiovascular diseases, with atherosclerosis as the underlying cause, are in Europe the most 
common cause of death in men under 65 years, and the second most common cause in 
women, and its prevalence is increasing in the developing countries. The concept of 
atherosclerosis being just a lipid storage disease leading to blockage of blood flow has 
predominated the thinking of the disease. During the past decades the crucial involvement of 
inflammation has been recognized. It is now evident that inflammation affects all stages of 
atherosclerosis: initiation, progression and eventually complications. Atherosclerosis has the 
same basic mechanisms as other inflammatory diseases, i.e. immune system secretes factors 
affecting  the  epithelial  and  mesenchymal  cells  of  the  organ  in  question.  In  the  case  of  
atherosclerosis, it is the vascular wall with its vascular endothelial cells and smooth muscle 
cells (SMC), respectively. This process leads to e.g. leukocyte recruitment, extracellular 
matrix (ECM) remodelling and cellular proliferation.  
 
The vascular wall is composed of three layers. Intima is lined with a monolayer of endothelial 
cells facing the lumen and internal elastic lamina on the peripheral side. Intima is mainly 
composed of ECM components, collagen and proteoglycans. The middle layer, media, 
contains SMCs, and the third layer, adventitia, is formed of connective tissues as well as 
fibroblasts and SMCs. (1) Atherosclerosis starts with accumulating lipids and immune cells 
into the intima, thus forming fatty streaks. These fatty streaks contain lipid-laden 
macrophages, so called foam cells. Fatty streaks may further progress into atherosclerotic 
lesions containing foam cells, dead cells, and lipid droplets. These components compose the 
core of the lesion which is surrounded by a fibrous cap containing collagen and SMCs. (1-3) 
Lesions first grow towards adventitia, after which they expand to lumen. They may grow, as 
mononuclear cells from the blood stream enter the lesion, and also due to cell proliferation, 
ECM production and further accumulation of lipids. Eventually, after years or even decades, 
the advanced lesion, atheroma, may rupture forming thrombus thus either partially or totally 
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blocking the blood flow to the tissue. Lesions mostly develop at the area where the blood flow 
is disturbed, such as arterial branching points, rather than in regions with laminar flow. (1,2,4) 
 
1.1.2. Overview of lipid metabolism 
 
The transport of cholesterol is mediated by different lipoprotein particles that are composed of 
lipids and apolipoproteins. The core of the particle is hydrophobic containing esterified 
cholesterol and triglycerides (TGs), and it is surrounded by a hydrophilic layer of 
phospholipids, free cholesterol and apolipoproteins. There are five major classes of 
lipoproteins: chylomicrons, very low density lipoproteins (VLDL), intermediate density 
lipoproteins (IDL), low density lipoproteins (LDL), and high density lipoproteins (HDL).  
 
Cholesterol comes from two sources: exogenously from the diet and endogenously by 
synthesis. Cholesterol received from the diet is absorbed in the intestine and packed into TG-
rich lipoproteins called chylomicrons (Figure 1). Chylomicrons are largely composed of TGs 
and to a lesser extent of cholesterol, and the main apolipoprotein is apoB-48. Lipoprotein 
lipase (LPL) bound to endothelium hydrolyzes TGs of chylomicrons in the circulation and the 
resulting chylomicron remnants are delivered to the liver. Hepatic cholesterol, which is 
mainly endogenously synthesized by the hepatocytes, is together with TGs packed as VLDL 
with apoB-100 being the major apolipoprotein (Figure 1). TGs of VLDL are further 
hydrolyzed by LPL resulting in the formation of VLDL remnants, IDL, which are either taken 
up by the liver or converted to LDL by hepatic lipase (HL). Approximately two thirds of 
plasma cholesterol is carried by LDL with apoB-100 being the predominating apolipoprotein. 
LDL functions as the source of cholesterol for steroidogenesis and cellular membranes. It is 
taken up by the liver or peripheral cells via apoB-100 recognizing LDL-receptor (LDLr). The 
liver clears LDL from the circulation, but excess amounts of LDL results in an elevated 
plasma cholesterol concentration. Unlike cells in the liver and the steroidogenic tissues, most 
cells are unable to metabolize cholesterol. Instead they regulate their LDL receptors in a way 
to control cholesterol content for membrane integrity and other functions. However, some cell 
types, such as macrophages can take up excess cholesterol via scavenger receptors resulting in 
the accumulation of cholesterol in e.g. arterial wall eventually leading to atherosclerosis. (5-8) 
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Cholesterol from peripheral tissues is transported to the liver for excretion by HDL in a 
process called reverse cholesterol transport (RCT). One third of the plasma cholesterol is 
carried by HDL, and approx. 70% of its total protein content is composed of apoA-I (6). Liver 
synthesizes and secretes apoA-I which interacts with ATP-binding cassette transporter A1 
(ABCA1) on the surface of peripheral cells, particularly macrophages, and the liver (Figure 1) 
(9). The naive lipid-free apoA-I is lipidated with free cholesterol and phospholipids forming 
partially lipidated discoidal HDL. HDL disk matures into spherical HDL via esterification of 
cholesterol by lecithin:cholesteryl acyltransferase (LCAT). HDL particles can accept 
cholesterol from the macrophages also via ATP-binding cassette transporter G1 (ABCG1) 
after lipidation of apoA-I by ABCA1 (10). From HDL, the formed cholesteryl esters (CEs) 
are either transported to the liver by hepatic scavenger receptor BI (SR-BI) for bile secretion, 
or to other lipoproteins containing apoB, such as LDL through cholesteryl ester transfer 
protein (CETP) which exchanges CEs for TGs (11). Phospholipids are transferred by 
phospholipid transfer protein (PLTP) from TG-rich lipoproteins to HDL during lipolysis by 
LPL.  PLTP  also  mediates  fusion  of  small  HDL  particles  into  larger  ones.  Mature  HDL  
particles are further modified by PLTP by removing phospholipids to maturing HDL and by 
HL that hydrolyzes TGs and phospholipids (Figure 1). Therefore, the actions of CETP, PLTP 
and HL remodel mature HDL particles releasing lipid-poor apoA-I for the next round of 
lipidation. (6,12,13) 
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Figure 1. Lipoprotein metabolism.  Modified from (14). 
 
1.1.3. Inflammatory mechanisms in atherogenesis 
 
1.1.3.1. Innate and adaptive immunity 
 
Both innate and adaptive immunity are involved in atherosclerosis. The innate immune 
response is a rapid, non-specific response to pathogen-associated molecular patterns 
(PAMPs), such as lipopolysaccharide (LPS) and modified LDL. Macrophages, the main 
effector cells of innate immunity, express patter recognition receptors, such as scavenger 
receptors and Toll-like receptors (TLRs). The ligation of scavenger receptors leads to 
endocytosis. TLR ligation activates e.g. nuclear factor-kappa B (NF-?B) pathway. These 
result in production of reactive oxygen species (ROS) as well as release of cytokines and 
adhesion molecules, which further affect the inflammatory status of the tissue. The innate 
immunity affects also the adaptive immunity as activated macrophages express major 
histocompatibility complex (MHC) class II antigens that are needed for antigen-dependent 
activation of T-cells. (15-18) 
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The other defence system, adaptive immunity, is slower and more specificly recognizing 
molecular structures and involving T- and B-cells. Antigen presenting cells (APCs), such as 
dendritic cells and macrophages present foreign antigens to T-cells, which thereafter produce 
a response specifically to that antigen. The response may be a cytotoxic T-cell attack against 
the cell bearing the antigen, stimulation of B-cell antibody production and induction of local 
inflammatory  response.  T-cells  can  differentiate  into  either  T  helper  1  (Th1)  or  T  helper  2  
(Th2) cells, Th1 cells being more prominent than Th2 in atherosclerotic lesion. (19-21) Th1 
cells secrete cytokines, of which interferon-gamma (IFN-?) is the most common and mediates 
the crosstalk between adaptive and innate immunity by stimulating macrophage production of 
ROS and pro-inflammatory cytokines such as tumor necrosis factor-? (TNF-?) and 
interleukin-1 (IL-1) (21,22). IFN-? also inhibits collagen production and cholesterol efflux, 
induces production of adhesion molecules, enhances T-cell and macrophage recruitment, lipid 
uptake by macrophages, activation of APCs, and proliferation of SMCs (2,20). Th2 cells, on 
the other hand, secrete cytokines such as IL-10, which also functions as an anti-inflammatory 
cytokine, that stimulate maturation of antibody-producing B-cells (21,23). They also may 
recruit and activate another inflammation-related cell type, namely mast cells (24). Another 
differentiated T-cell form, regulatory T-cell, suppresses the functions of other immune cells 
and secretes transforming growth factor ? (TGF-?), an atheroprotective cytokine whose 
targets in atherosclerosis are mainly T-cells, but also endothelial cells, dendritic cells, SMCs 
and macrophages. It also stabilizes lesions via increased collagen synthesis and MMP 
inhibitor production. T-cell activation is not necessary for the initiation but for the early 
progression of atherosclerosis. (2,22) 
 
1.1.3.2. Effects of inflammation on the initiation and progression of atherosclerosis 
 
The initial step in the formation of atherosclerosis is adhesion of monocytes to the vessel wall 
(Figure 2). Normal, healthy vessels can resist the adhesion. However, in situations that trigger 
atherogenesis, such as lipid accumulation into the intima due to diet and modification of LDL, 
smoking, hypertension, insulin resistance, microbes, or pro-inflammatory cytokines (such as 
TNF-? and IL-1?), endothelial cell expression of adhesion molecules results in the monocyte 
attachment (1,25). The adhesion molecules include vascular cell adhesion molecule-1 
(VCAM-1), intercellular adhesion molecule-1 (ICAM-1), and P- and E-selectins. After the 
endothelium binding, a chemokine called monocyte chemoattractant protein-1 (MCP-1) 
secreted by endothelial cells, SMCs, and macrophages, recruits monocytes which penetrate 
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the endothelium and enter the intima causing accumulation of monocytes. Once in the intima, 
macrophage colony-stimulating factor (M-CSF) induces monocyte maturation into 
macrophage and macrophage proliferation. Both MCP-1 and M-CSF are overexpressed in 
atherosclerotic lesions (26-29). Macrophages start to increase expression of TLRs and 
scavenger receptors. Scavenger receptors internalize modified LDL resulting in cholesterol 
ester accumulation in the cytoplasm and converting the cells into so-called foam cells, lipid 
laden macrophages associated with the early atherosclerotic lesion formation. Signals through 
TLRs lead to macrophage activation and mediate the release of cytokines, proteases, and 
ROS. (1,15,30) This cascade leads to the formation of fatty streaks that are asymptomatic and 
found already in young people, but do not necessarily progress to more advanced 
atherosclerotic lesions (31). 
 
 
Figure 2. Monocyte recruitment and foam cell formation. Reproduced with permission from 
(32). 
 
In the intima, macrophages secrete e.g. ROS and cytokines that sustain the inflammatory 
status in the vessel wall. The inflammatory status is further supported by pro-inflammatory 
cytokines produced by T-cells. Pro-inflammatory signals also induce production of 
inflammatory mediators by endothelial and SMCs. (16) During the progression of 
atherosclerosis, CD40 ligand (CD40L) participates in the immune response. T-cell CD40L 
ligates with B-cell CD40 leading to reduced B-cell apoptosis, enhanced B-cell amplification, 
and activated T-cell pro-inflammatory cytokine production (33). CD40 and CD40L are 
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expressed also in macrophages, vascular endothelial cells and SMCs (34,35). CD40L 
regulates the expression of adhesion molecules, cytokines, and chemokines, as well as 
induces MMP and tissue factor production, all involved in the atherogenesis (1,36-41). T-cells 
are always present in atherosclerotic lesions, especially CD4+ cells that recognize MHC class 
II bound antigens (19). Human atherosclerotic lesions have been shown to contain CD4+ cells 
reactive to Chlamydia pneumoniae proteins, oxidised (ox)-LDL, and Porphyromonas 
gingivalis heat-shock protein (HSP) 60 (42-44) . 
 
The main structure protecting the atherosclerotic lesion is the fibrous cap. It can resist the 
function of most proteases, but some MMPs are capable of initiating the cleavage of the triple 
helical molecule structure of collagen, the main component of the cap. Activated 
macrophages, SMCs, and endothelial cells present in atherosclerotic lesions express several 
MMPs that can degrade the collagen structure of the cap (45-48). Several inflammatory 
mediators, such as an acute phase protein serum amyloid A (SAA), TNF-?, and IL-1, are able 
to induce the expression of MMPs (46,47,49). In addition to collagen degradation, also the 
collagen synthesis is reduced due to pro-inflammatory cytokines. T-cells affect both the 
collagen degradation by activating macrophages and the reduced collagen synthesis by e.g. 
IFN-? -mediated inhibition of collagen messenger ribonucleic acid (mRNA) expression 
(22,50). Once the cap has ruptured, the thrombotic core of the lesion is exposed and released 
to the lumen enabling the interaction between macrophage-derived tissue factor and blood 
resulting in coagulation and thrombus (51). Inflammatory processes are thus present in all 
stages of atherosclerosis: initiation, progression, and the actual CVD event. 
  
1.1.4. Mouse as an atherosclerosis model 
 
Basic research of atherosclerosis is mostly based on animal models as studying it in humans is 
difficult due to its complexity, chronicity and impossibility to characterize lesions 
sequentially. A number of animal models have been used, such as pigs and rabbits, but the 
most widely used are mice. Mice have the advantage of being easy, fast and economical to 
breed, easy and economical to maintain, their environment and diet can be controlled, the 
genetic information on many inbred strains is available, and they are the most widely used 
mammals in experiments involving genetic manipulations. Also the size of the animal permits 
studies on e.g. pharmacological agents to be carried out, as novel drugs are not synthesized in 
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large quantities and are therefore sufficient only for studies in small animals. Due to the size 
and easy maintenance, group numbers and animal numbers in the groups can be large, which 
is necessary to achieve reliable data. This is particularly important in atherosclerosis studies, 
as the lesion sizes vary greatly due to large natural variance. Other drawbacks associated with 
the small body size are the low amount of blood available, small tissue sizes for analyzation, 
and restricted surgical possibilities. (52,53) 
 
Probably the main disadvantage of mice in atherosclerosis research is that they do not develop 
atherosclerosis spontaneously. Mice are HDL animals carrying most of their cholesterol in 
HDL, whereas humans have approximately 70% of their plasma cholesterol in LDL. In inbred 
mice strains, the capability to develop diet-induced atherosclerosis varies greatly, C57Bl/6 
strain being the most susceptible. Yet, feeding of a long term lipid-enriched diet causes lesion 
growth only in the aortic root in C57Bl/6 mice. This has been overcome by generating 
genetically modified strains where larger lesions form either spontaneously or after proper 
diet. These include apoE-/- mice with C57Bl as a background strain. However, no mouse 
strain has been observed to develop plaque rupture in spite of the presence of intraplaque 
hemorrhage in mature lesions. (53,54)  
 
There are some differences between humans and mice from the atherosclerotic point of view. 
As mentioned, wild type mice are HDL animals, mostly due to the lack of CETP. This makes 
them generally resistant to atherosclerosis. Genetically modified mouse strain expressing 
CETP has an increased cholesterol content of VLDL and LDL. In humans, liver produces 
only apoB-100, whereas in mice both apoB-100 and its shorter form apoB-48 are produced; in 
humans apoB-48 is produced in the intestine. The structure of apoA-II differs, as it is dimeric 
in humans and monomeric in mice. Mice also lack lipoprotein(a). Humans produce HL in the 
liver and it is bound to hepatocytes and hepatic endothelial surfaces, whereas it is free in the 
circulation in the mice. Atherosclerotic plaques are most frequently present in murine aorta 
and not in coronary arteries like in humans, and they also develop much faster in mice 
compared to those in humans. The plaques do not necessarily cause symptoms seen in 
humans, such as myocardial infarction (MI), cardiac dysfunction and occlusive coronary 
artery disease. (52) However, a double knockout model (SR-BI-/-/apoE-/-) has developed a 
complete coronary artery occlusion resulting in MI, reduced heart function, cardiac 
conductance defects and early death (55). In addition, there are many immunological 
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differences between mice and humans (56) and also the endotoxin dose must be many times 
higher in mice than in men to induce corresponding effects (57).  
 
The most widely used mouse model in atherosclerotic research is apolipoprotein E deficient 
(apoE-/-) mice that was generated in 1992 by inactivating the gene in mouse embryonic stem 
cells via homologous recombination (58). ApoE is present in lipoprotein particles being a 
major component of VLDL, and serves also as a ligand to LDL-receptor thereby enabling the 
uptake of apoE-containing particles by the liver. As a result of this, the characteristics of 
apoE-/--mice include increased total cholesterol (approx. 8-11 mmol/l compared to 2 mmol/l 
in C57Bl/6) and triglyceride concentrations and decreased HDL cholesterol concentration on 
a regular chow diet. These mice show very early, at the age of 5-6 weeks, monocyte adhesion 
and migration. Fatty streaks with foam cells and migrating SMCs start to appear in 6-10 
week-old mice. Lesions grow rapidly to advanced lesions with a necrotic core surrounded by 
proliferating SMCs and ECM. The plaques appear along the entire arterial tree; more 
pronounced plaques appearing in the aortic arch and in the aortic sinus. In older mice, lesions 
have calcified foci. At the age of one and half years, the occlusion of arteries can be as high as 
90%. If these mice are given diet enriched with fat, the progression of lesions accelerates 
significantly with occlusions appearing in less than one year. As previously mentioned, the 
genetic background influences the susceptibility to develop atherosclerosis, and therefore the 
most widely used background in apoE-/- mouse is the C57Bl/6. The lipoprotein profile of 
apoE-/- mice  differs  from  that  of  humans,  as  they  carry  most  of  their  plasma  cholesterol  in  
VLDL. However, their suitability as an atherosclerotic model is well justified as their lesion 
progression and cell types as well as oxidized lipoproteins are similar to those found in 
humans. (52-54,59,60) 
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1.2. Infection in atherosclerosis 
 
1.2.1. Background 
 
Atherosclerosis is an inflammatory disease, and one of the culprits may be infections caused 
by pathogens. As early as in the 1970s germ-free chickens infected with avian herpesvirus 
were found to produce human atherosclerosis-like disease (61). Since then, several pathogens 
have been associated with CVD such as Chlamydia pneumonia, periodontal pathogens, 
cytomegalovirus (CMV), and Helicobacter pylori.  
 
Pathogens may be linked to development and progression of atherosclerosis by several 
mechanisms. Most investigations are based on seroepidemiological studies, but it has also 
been shown, that infectious agents may reside in the vessel wall e.g. by invading endothelial 
cells, like in case of C. pneumoniae and periodontal pathogens (62-66). CMV infection can 
cause SMC replication probably by inhibiting tumour suppressor gene p53, as its product 
inhibits cell cycle progression, or by enhancing growth factor secretion or receptor expression 
(67,68). Both CMV and C. pneumoniae are able to inhibit apoptosis of infected cells and 
CMV has also been shown to increase SMC migration; both factors affecting the mass growth 
of lesions (67,69,70). Infections and LPS also cause accumulation of lipids in macrophages 
due to down-regulation of SR-BI and ABCA1, whereas scavenger receptor type A (SR-A) is 
up-regulated in inflammation (71-77). Infections result in a release of cytokines, chemokines, 
and cellular adhesion molecules thus making the endothelium more susceptible to monocyte 
adhesion (78,79).  
 
One pathogen is, however, unlikely to solely cause development and/or progression of 
atherosclerosis. Several seroepidemiological studies have shown that multiple infections, so 
called infectious burden, increases the risk for cardiovascular diseases. There is a correlation 
between the number of pathogens, both viruses and bacteria, patients are exposed to and the 
risk for coronary artery disease (CAD), elevated C-reactive protein (CRP) concentrations, 
extent of atherosclerosis, and cardiovascular death (80-82). 
 
One mechanism, which may contribute to atherosclerotic lesion development due to infection, 
is molecular mimicry, where pathogen contains a structure homologous to that in a host 
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protein resulting in production of autoantibodies. Especially pathogen-derived HSPs, HSP60 
or GroEL, have been shown to cross-react with human HSP60, as in case of Helicobacter 
pylori, CMV, Escherichia coli, C. pneumoniae and periodontal pathogen Porphyromonas 
gingivalis (83-86). High antibody titers against HSPs are linked to atherosclerosis, and 
endothelial cells ubiquitously express HSP60 in response to blood pressure, 
hypercholesterolemia, cytokines, low-shear stress and LPS (87,88). Molecular mimicry also 
exists between epitopes of oxidized LDL (ox-LDL) and Streptococcus pneumoniae (89). As 
all bacteria have HSPs, and they are highly conserved, it is likely that many other pathogens 
may also be involved in these inflammatory reactions. Altogether, pathogens may induce an 
inflammatory status in the arterial wall leading to atherosclerosis via mechanisms described in 
section 1.1.3.  
 
1.2.2. Periodontitis 
 
1.2.2.1. Introduction 
 
Periodontitis is a chronic bacterial infection affecting gingiva and tooth-supporting tissues. It 
is an infection of multiple, mostly gram-negative anaerobic bacterial species, such as 
Aggregatibacter (previously Actinobacillus) actinomycetemcomitans, Porphyromonas 
gingivalis, Prevotella intermedia, and Tannerella forsythia (previously Tannerella 
forsythensis) (90). Over 700 different bacterial species present in dental pockets have been 
cultured (91,92). Periodontal infection initiates as plaque at gingival margin gradually 
transform to dental calculus and finally invades and degrades the connective tissue and bone 
support (Figure 3). The loss of tooth support is mainly due to host defence, such as secretion 
of proteases, and results in formation of deepened periodontal pockets. If the disease is not 
treated,  it  will  lead  to  loss  of  teeth.  Periodontitis  is  a  common  disease  worldwide;  
approximately 10% of adult population and 30% of people over 50 years of age suffer from 
severe periodontitis (93,94). In Finland, 64% of adults have signs of periodontitis, and the 
severe forms affect 21% of the adult population (95).  
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Figure 3. Periodontitis. The host response to periodontal pathogens and dental calculus leads 
to reduction of connective tissue and bone support resulting in deepened periodontal pockets 
and attachment loss. 
 
1.2.2.2. Periodontitis and cardiovascular diseases 
 
Periodontitis has been proposed to be one of the infections associated with atherogenesis, and 
it was initially suggested by Mattila et al in 1989 (96). Periodontal pathogens and their LPS 
continuously have a direct access to the systemic circulation via inflamed periodontal pockets 
as a result of e.g. tooth-brushing and eating, thereby inducing systemic inflammation and LPS 
responses as described in section 1.2.5. This theory is supported by the fact that periodontal 
pathogens and their deoxyribonucleic acid (DNA) have been found in human atherosclerotic 
lesions (97-99) and that they are able to invade aortic endothelial and smooth muscle cells in 
vitro (65,66,100) thus likely affecting the endothelial integrity. Proinflammatory cytokines 
released from inflamed periodontal pockets may induce inflammatory effects not only locally 
but  also  systemically  (101),  and  for  example  CRP,  a  risk  factor  for  CVD,  is  elevated  in  
periodontal patients compared to periodontally healthy subjects (102). Periodontitis and the 
resulting inflammatory cytokines can also induce endothelial dysfunction and platelet 
aggregation, that are also CVD risk factors (101,103,104). Several studies have shown that 
periodontitis or exposure to periodontal pathogens increase the risk for CVD as well as cause 
increase in intima-media thickness (IMT), which can be considered as a marker of subclinical 
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atherosclerosis (105-108). Periodontitis also affects lipid metabolism. It associates with 
increased LDL and TG levels and decreased HDL concentration as well as macrophage 
activation and foam cell formation (73,109-114). After periodontal treatment, many 
atherosclerosis-related markers improve, including CRP and other inflammatory mediators, 
cholesterol concentrations, and LDL particle sizes (111,112,115,116) further implying the 
systemic and proatherogenic effects of periodontitis. 
 
1.2.2.3. Aggregatibacter actinomycetemcomitans and atherosclerosis 
 
One major periodontal pathogen is Aggregatibacter actinomycetemcomitans, a facultative, 
gram-negative anaerobe. It is especially prevalent in juveline periodontitis as approximately 
90% of these patients carry A. actinomycetemcomitans compared to 50% of adult patients, but 
it may also be present in healthy individuals in lower proportions (117,118). Several human 
and animal studies have implied the possible role for A. actinomycetemcomitans in CVD. In 
serological studies antibodies to A. actinomycetemcomitans associate with prevalent CVD 
(119-121) as well as increased risk for future CVD events such as stroke, coronary heart 
disease (CHD), and MI (108,122,123). A. actinomycetemcomitans has been detected by 
immunohistochemistry (124) and by polymerase chain reaction (PCR) (97,125-129) from 
vascular tissues of CVD patients. Furthermore, viable bacteria have been isolated from human 
atherosclerotic plaques (98). According to Spahr et al. the periodontal pathogen burden, 
assessed by DNA-DNA hybridization, and especially the presence of A. 
actinomycetemcomitans, is associated with increased risk of CHD (130). A recent study 
concerning MI and antibodies against periodontal bacteria also showed the significance of 
presence of several bacterial strains instead of just one (131). Despite of the clinical 
significance of A. actinomycetemcomitans, there are only a few animal studies concerning the 
association of the pathogen and CVD. These studies, however, show that A. 
actinomycetemcomitans e.g. induces mast cell activation in the aortic sinus (132).  
 
1.2.2.4. Porphyromonas gingivalis and atherosclerosis 
 
P. gingivalis is a gram-negative obligate anaerobe, and is especially associated with adult 
aggressive and chronic forms of periodontitis. Its atherogenic effects have been studied 
extensively. P. gingivalis serology not only shows association between exposure to P. 
gingivalis and prevalent CVD (119,133,134), but also the risk for future CVD events, such as 
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stroke and MI (108,122,123,135,136). The presence of P. gingivalis in atherosclerotic plaques 
has been verified immunohistochemically and by PCR (97,124,127,128,137). Also, like A. 
actinomycetemcomitans, viable invasive P. gingivalis bacteria have been identified in human 
atherosclerotic plaques (98). In animal studies, P. gingivalis given to apoE-/- mice either 
orally, anally (due to coprophagic nature of mice), or intravenously (i.v.) results in accelerated 
atherosclerosis, occurence of bacterial ribosomal DNA in the aortas, livers and hearts, and 
increased expression of aortic VCAM-1, tissue factor, TLR-2 and TLR-4 (138-140). 
Atherosclerotic lesion development has also been detected in rabbits and pigs infected with P. 
gingivalis (141,142). The pathogen could, furthermore, be detected in pig arteries by PCR 
(142). Overall the results indicate that the continuous access of periodontal pathogens to the 
blood stream may affect the initiation and progression of atherosclerosis. 
 
1.2.3. Chlamydia pneumoniae 
 
1.2.3.1. Introduction 
 
The order Chlamydiales comprises a large number of bacteria that have a common feature of 
obligate growth in eukaryotic cells. The order classically contains one family, 
Chlamydiaceae, one genus, Chlamydia, and four species, C. trachomatis, C. pneumoniae, C. 
psittaci, and C. pecorum (143). A more recent, and controversial, proposed taxonomy divides 
the family Chlamydiaceae into two genera, Chlamydia containing three and Chlamydophila 
six species, and additional three new families would be formed from Chlamydia-like bacteria 
(Waddliaceacae, Parachlamydiaceae, and Simkaniaceae (144). In this taxonomy, Chlamydia 
pneumoniae is part of the genus Chlamydophila, but the new classification has also been 
considered unnecessary (145). 
 
C. pneumoniae is a gram-negative bacterium causing respiratory tract infection, and studies 
concerning prevalence of antibodies to C. pneumoniae show that the infection rate is high; 
approximately 70-80% of elderly people are seropositive, males more often than females, but 
it is less common in children under five years in industrialized countries (146). The 
manifestations of the disease are numerous, as it can vary from asymptomatic to life-
threatening pneumonia (147). C. pneumoniae is transmitted as metabolically inactive particle 
which differentiates, replicates, and re-differentiates in a host cell. C. pneumoniae has two 
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forms,  the  elementary  body (EB)  and  the  reticulate  body (RB).  The  infectious  form,  EB,  is  
small (ca. 0.3 µm), round, and metabolically inert. It invades the host cell and is internalized 
in a vacuole called inclusion. Inside the cell, EB differentiates into the metabolically active, 
non-infectious RB that is larger (ca. 1 µm) and divides repeatedly (‘binary fission’). RBs 
undergo secondary differentiation back to EBs that are released upon cell lysis and are able to 
infect the surrounding cells. In chronic state, Chlamydia is associated with the host cell 
staying in a viable but culture-negative form. (148) C. pneumoniae infection is suggested to 
be linked to several diseases, one of them being atherosclerosis. 
 
1.2.3.2. Chlamydia pneumoniae and atherosclerosis 
 
The association between C. pneumoniae and atherosclerosis was initially proposed by Saikku 
et al. over twenty years ago, when they discovered elevated antibody response in patients with 
acute myocardial infarction (AMI) or chronic CHD (149). Since then, the research concerning 
this association has bloomed, and dozens of seroepidemiological studies have further verified 
the concept. A stronger evidence of this association has come from the studies showing the 
presence of C. pneumoniae in e.g. atherosclerotic plaques. The first evidence of the presence 
of C. pneumoniae in lesions came from transmission electron microscopy study of 
atherosclerotic lesions from autopsy tissues (150) that was later confirmed by 
immunohistochemistry and PCR (62). The viability of C. pneumoniae in lesions was shown 
few years later, as viable bacteria from coronary artery were cultured; the presence of bacteria 
was demonstrated also by PCR, immunohistochemistry, electron microscopy, and in situ 
hybridization (151). Viable C. pneumoniae has also later been detected in atherosclerotic 
lesions (152). As many as almost 60% of atherosclerotic lesions contain C. pneumoniae 
compared to 3% in normal vessel wall (153). PCR results can vary greatly between studies, 
but altogether the data clearly indicate the presence of C. pneumoniae in atherosclerotic 
lesions thereby likely contributing to proatherogenic changes. However, not all studies have 
confirmed this association between C. pneumoniae and atherosclerosis (154). 
 
Basically two animal models have been used in C. pneumoniae studies concerning 
atherosclerosis, that is rabbits and mice. New Zealand white rabbits show early atherosclerotic 
changes such as foam cell formation in the aortic arch (155) and intimal thickening (156,157) 
after C. pneumoniae inoculations. In mouse studies, hyperlipidemic strains such as apoE-/- 
show more advanced lesions (158-160), as well as in LDLr-/- (161,162), apoE3-Leiden (163), 
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and wild type (164-166) mice fed a cholesterol-rich diet. In contrast, in normolipidemic mice 
C. pneumonia do infect and induce inflammatory changes in the aorta, but do not show 
indications of further lesion progression (167,168) indicating the importance of cholesterol in 
the ability of C. pneumoniae to induce proatherogenic changes.  
 
The mechanism by which C. pneumoniae contributes to atherosclerosis may be partly 
explained by its ability to enter vasculature and vascular wall via monocytes and lymphocytes 
(169). C. pneumoniae is  able  to  infect  and  replicate  in  endothelial  and  SMCs,  as  well  as  in  
macrophages (64,170). It also increases endothelial expression of adhesion molecules (79) 
and enhances attachment of infected monocytes to the endothelium (171). C. pneumoniae 
causes LDL oxidization (172,173) and its LPS induces macrophage foam cell formation (72). 
All these effects cause inflammatory response of the vasculature and thus enhance 
atherogenesis. 
 
1.2.4. Lipopolysaccharide 
 
Lipopolysaccharide is the outer membrane structure of gram-negative bacteria, and it is also 
termed as endotoxin. Gram-negative bacteria are common human pathogens, including 
Escherichia coli, Salmonella enterica, C. pneumoniae, P. gingivalis, and A. 
actinomycetemcomitans which colonize human gastrointestinal, genitourinary, oral cavity, 
and respiratory tracts and produce endotoxins not only during clear infections but also during 
chronic inflammatory conditions. The outer membrane of gram negative bacteria is a bilayer 
composed of mainly LPS containing outer leaflet and inner leaflet rich in phospholipids and 
proteins. The functions of the outer membrane are to communicate with the environment by 
harbouring and transporting nutrients, protecting the bacteria from toxic compounds such as 
antibiotics, or interacting with the host. LPS also causes the physiological effects, such as 
fever, during infection and it can be released from the bacteria upon multiplication or death 
and lysation. (174,175) 
 
1.2.4.1. Structure of LPS 
 
LPS is composed of three regions: O-specific side chain, core oligosaccharide, and lipid A, of 
which O-side chain protrudes outwards and lipid A attaches LPS to the bacterium (Figure 4). 
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The O-side chain is a heteropolysaccharide consisting of repeating oligosaccharide units, and 
possesses therefore an enormous variability. Carbohydrate residues in each repeating unit 
have different antigenic properties; these are called ‘O-factors’. Several O-factors can be 
present in one repeating unit thus determining the serotype of the bacteria. The core region 
consists of heterooligosaccharide and is less variable than the O-side chain. The most 
conserved part of LPS is the lipid A, the bioactive component of LPS causing fever and lethal 
toxicity. (176) It is also responsible for macrophage activation and most of the endotoxic 
effects of LPS, which actually appear due to macrophage activation and the following 
cytokine as well as ROS release. LPS interacts not only with macrophages but also with e.g. 
B-cells, T-cells, vascular endothelial and SMCs (174,175,177) inducing the production of 
pro-inflammatory cytokines and adhesion molecules (178,179).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Structure of LPS. 
 
1.2.4.2. Receptors of LPS-mediated signalling 
 
For mediating signals to cells, LPS forms a complex with several proteins, i.e. LPS binding 
protein (LBP), CD14, TLR-4, and MD-2. Together these proteins initiate the signalling that 
via activation of kinases results in the activation of NF-?B. LBP binds LPS and delivers it to 
CD14 or lipoproteins (180,181). LPS-CD14 complex further reacts with membrane bound 
TLR-4 and its co-receptor MD-2, which binds both to TLR-4 and LPS (182,183). In 
periodontal patients the concentration of soluble CD14 is elevated (184) indicating an 
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increased LPS exposure. TLR-4 is expressed and mediates LPS response in vascular 
endothelial cells, and it is also present in lipid rich atherosclerotic plaques containing 
macrophages (185-187). Not only LPS, but also e.g. HSP60, fibronectin, minimally modified 
LDL, and saturated fatty acids can function as ligands for TLR-4 (188-190). The induction of 
NF-?B leads to the activation of e.g. interleukins, adhesion molecules, MCP-1, and MMPs 
(15). Activation of TLR also blocks liver X receptor (LXR) target gene ABCA1 (191), thus 
affecting the cholesterol efflux.  
 
1.2.4.3. LPS neutralization and clearance by lipoproteins 
 
LPS is cleared from the circulation by lipoproteins which receive LPS from LBP or PLTP 
(181,192,193). LPS binds via lipid-A to lipoproteins, predominantly to HDL, but clearly also 
to LDL and VLDL (177,194). LPS binds rapidly to HDL, and it is further redistributed mainly 
to LDL by PLTP (194,195). In septic conditions, but also in periodontitis, when HDL 
concentration is lowered, the binding of LPS is sifting towards VLDL and its overall transfer 
rate to lipoproteins is accelerated (114,196,197). The main factor in neutralizing the LPS 
activity is the phospholipid content of the lipoproteins together with apolipoproteins, such as 
apoE and apoA-I (14,198). Indeed, one function of lipoproteins is to protect the body from 
lethal dose of LPS; TG-rich lipoproteins transfer LPS further to hepatocytes, where it is 
deactivated and secreted into bile (199-202).  
 
1.2.5. Infection and lipid metabolism 
 
Infection and inflammation alter lipid and lipoprotein metabolism. During acute phase 
response (APR), plasma triglyceride and VLDL levels increase whereas HDL concentration 
decreases. The increased TG concentration is likely to result from increased VLDL either due 
to  increased  VLDL  production  or  impaired  VLDL  clearance.  In  rodents,  low  LPS  dose  
enhances VLDL production by enhancing lipolysis of adipose tissue, increasing hepatic FA 
synthesis, and lowering hepatic FA oxidation, whereas high LPS dose reduces LPL activity 
resulting in diminished VLDL clearance. (203-205). VLDL clearance is further affected by 
the infection-related reduction in apoE expression (206). 
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The composition and structure of lipoproteins are also affected by infection. VLDL and LDL 
are enriched with sphingolipids making them more likely proatherogenic (207,208). LDL 
particles become small and dense being thus more easily oxidized (209), having reduced 
LDLr binding affinity (210), and having capability to penetrate the endothelium and to 
effectively bind proteoglycans in the intima (211). These changes enhance the accumulation 
of LDL particles in the arterial wall and foam cell formation. 
 
HDL functions as an anti-atherogenic lipoprotein as it i) mediates RCT, ii) scavenges or 
breaks down oxidized phospholipids, iii) suppresses the induction of adhesion molecules, iv) 
reduces ROS expression, v) increases endothelial nitric oxide synthase (eNOS) activity and 
concentrations, as well as reverses the ox-LDL-mediated decrease in nitric oxide (NO) 
production, vi) has anti-thrombotic properties, and vii) represses apoptosis of endothelial cells 
(212,213). In APR, HDL is remodelled converting it from anti-inflammatory to pro-
inflammatory lipoprotein. As HDL mediates RCT, the processes involved in modification of 
HDL or other components related to RCT may thus have adverse effect on cholesterol export 
from peripheral cells to the liver.  
 
During APR, in HDL particles apoA-I is replaced by SAA resulting in a decrease in apoA-I 
concentration (214,215). Anti-inflammatory enzymes associated with HDL, such as 
paraoxonase-1 (PON-1) and platelet-activating factor acetylhydrolase that otherwise inactive 
oxidized lipids are decreased in acute-phase HDL (216,217). Pro-inflammatory cytokines co-
ordinate the reciprocal hepatic expression of SAA, apoA-I, and PON-1; they increase SAA 
expression and at the same time decrease apoA-I and PON-1 expression (218). Lipid-free 
SAA promotes cholesterol efflux not only via ABCA1 like apoA-I, but unlike apoA-I, also in 
a ABCA1- and energy-independent way (219). There are, however, conflicting results 
concerning the of role SAA in RCT, as some studies indicate it to increase RCT (220-222), 
whereas others suggest the opposite (223-225). However, HDL enriched with SAA binds 
rather macrophages than hepatocytes (226). SAA functions also as a chemoattractant alluring 
inflammatory cells to the site of inflammation (227,228). It has been suggested that in acute 
inflammation increased SAA may be beneficial, but deleterious if chronically increased as in 
type 2 diabetes (229). 
 
During inflammation, apoA-I may be modified by macrophage-derived myeloperoxidase, 
MPO, leading to decreased ability of HDL to remove cholesterol via ABCA1 (230,231). 
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Khovidhunkit et al have shown, that endotoxin or cytokines, TNF-? and IL-1, decrease both 
ABCA1 and ABCG1 mRNA as well as their protein levels in J774 murine macrophages (75) 
therefore reducing cholesterol efflux. HDL concentration decreases in APR e.g. due to 
remodelling of HDL by an acute phase protein group IIa secretory phospholipase A2 (sPLA2-
IIa) as it has been shown to increase HDL catabolism (232). It also converts LDL into small, 
dense and thus more atherogenic particles (233). sPLA2-IIa has been detected in 
atherosclerotic lesions (234). However, mice with C57Bl/6 genetic background have a point 
mutation making the sPLA2-IIa non-functional (235).  
 
The scavenger receptors of macrophages are involved in the uptake of modified LDL (236). 
Class A scavenger receptors SR-AI and SR-AII are expressed in macrophages, including 
foam cells, as well as in aortic endothelial cells and vascular SMCs. They are involved in the 
uptake of acetylated and ox-LDL as well as recognizing gram-negative bacteria (237-239). 
Class B receptor CD36 binds e.g. moderately ox-LDL, as well as native lipoproteins 
(240,241) and its function is required for foam cell formation (242). Another class B receptor, 
SR-BI is involved in selective cholesterol transfer to and from HDL (11), as previously 
described in RCT. Both receptor classes are affected by LPS administration, which in 
experimental research mimicks infection; SR-A expression is upregulated (243), whereas 
hepatocytic SR-BI expression is decreased (74) (Figure 5). In the RAW 264.7 macrophage 
cell line LPS stimulation causes a decrease in SR-BI mRNA level resulting in either 
unchanged or decreased protein levels (73,74,76). APR affects also enzymes related to 
cholesterol  metabolism.  It  lowers  the  activities  of  HL,  LPL  (244),  CETP  (245),  and  LCAT  
(246), and increases PLTP activity (247). The effects of infection on lipid metabolism are 
summarised in Figure 5. Due to all these effects infection has on lipid metabolism, the lipid 
accumulation increases in peripheral tissues and atherosclerosis development progresses. 
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Figure 5. Effects of infection on lipid metabolism. PLTP activity has been shown to decrease 
in mouse and increase in human. Modified from (14). 
 
 
1.2.6. Endothelial function 
 
Healthy vascular endothelium has diverse functions. It participates in the vasodilation, and 
inhibits adhesion and migration of circulating leukocytes, proliferation and migration of 
SMCs, and adhesion and aggregation of platelets (248). These functions are compromised in 
endothelial dysfunction that is a marker of atherosclerosis. 
 
One key function of endothelium is vasodilation. The key regulator of vasodilation is NO, 
which is synthesized from L-arginine by eNOS present in the lipid rafts called caveolae (249). 
In inflammation LDL is oxidized and this ox-LDL induces translocation of eNOS by taking 
up caveolae cholesterol via CD36 making stimulation of eNOS impossible (250). This can, 
however, be prevented by HDL (251) which binds SR-BI in caveolae resulting in activation 
of eNOS (252); normal caveolae cholesterol levels and eNOS association are thus maintained. 
This may be disturbed in atherosclerosis as HDL is modified and its concentration decreases 
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at the same time as ox-LDL concentration increases thus affecting the vasodilation properties 
of vasculature. Also inflammatory mediators, such as TNF-?, downregulate the activity of 
eNOS (253), as well as increase the production of ROS which is able to reduce NO activity 
(254,255). Oxidative stress also increases the concentration of asymmetric dimethylarginine 
(ADMA), an endogenous eNOS inhibitor, (256). As both native and ox-LDL increase ADMA 
concentration, lipid accumulation may affect endothelial function via ADMA (257,258). 
 
Another marker of endothelial dysfunction is increased expression of adhesion molecules, 
which attract inflammatory cells to the site of inflammation. The upregulated molecules 
include e.g. selectins (P- and E-selectin) and various adhesion molecules, such as ICAM-1, 
VCAM-1, and platelet endothelial cell adhesion molecule-1 (PECAM-1). E-selectin is 
associated with the rolling of cells and it is expressed both in acute and chronic endothelium, 
but is not constitutively expressed under normal conditions (259). It is expressed in 
endothelial cells upon exposure to inflammatory cytokines, such as TNF-?, and oxidative 
stress, and it has been found on the surface areas of plaques (260,261). The adhesion is 
mediated by VCAM-1 and ICAM-1 that are upregulated by TNF-?, disturbed oscillatory flow 
common in the regions with atherosclerotic plaques, and by exposure to ox-LDL (88,262-
264).  
 
Infections affect endothelium in several ways. In fact, it has been shown, that infections, and 
particularly infection burden, correlate with the severity of endothelial dysfunction (265). 
Also other studies with e.g. vaccination or endotoxin administration show impaired 
endothelial function (266). Patients with impaired endothelial function have increased risk for 
future cardiovascular events (267). Correspondingly, treatment of atherosclerosis, 
hypercholesterolemia or chronic infections improves endothelial function (268-270).  
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1.3. Steatosis 
 
1.3.1. Introduction 
 
Liver takes up lipids both as free fatty acids (FFAs) and lipoprotein particles. Some 
lipoprotein particles are taken up by endocytosis whereas in others the TGs are hydrolyzed by 
HL producing FFAs that are able to diffuse or be transported to the liver. Liver also has de 
novo FA synthesis by fatty acid synthase (FAS), whose expression is regulated by sterol 
regulatory element-binding protein (SREBP)-1c. (271,272) Free fatty acids may further be 
oxidized by ?-oxidation thus producing both energy and ketone bodies. They may also be 
used as building blocks for phospholipids and mediators (e.g. prostaglandins and 
leukotrienes) whereas the carbon skeletons can be utilized in glucose and cholesterol 
production. FFAs may also be converted to TGs for VLDL production, and the amount of 
exported VLDL depends not only on the availability of TGs, but also on synthesis of protein 
components. The protein component of VLDL, apoB, is degraded by insulin action, and 
SREBP-1c inhibits the formation of microsomal triglyceride transfer protein (MTTP), that 
catalyzes the lipidation of apoB. The excess TGs are stored as lipid droplets in the 
hepatocytes. (273)  
 
A substantial source of FFAs is a circulation, where FFAs from dietary fat and adipocytes 
through  lipolysis  of  stored  TGs,  are  available.  If  serum  FFA  levels  are  elevated  for  a  long  
period, the liver FA intake may be increased. This may be the case in insulin insensitive or 
resistant state, such as type II diabetes. (274) Steatosis is a liver condition manifested by TG 
accumulation in the hepatocytes. As previously described, liver has a key role in lipoprotein 
metabolism. In steatosis, the FA cycle is distorted resulting in fat accumulation into the liver. 
Steatosis is defined as a nonalcoholic fatty liver disease (NAFLD), when it develops without 
excess use of alcohol. It is one of the most common liver diseases worldwide, its prevalence 
being 20-25% in the general population. Increasing with age, NAFLD tends to be more 
common in males than in females (275,276). Diabetes and obesity are closely associated with 
NAFLD, as half of diabetics and approximately 75% of obese people have NAFLD (277-
279).  
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1.3.2. Nonalcoholic fatty liver disease 
 
The spectrum of NAFLD extends from simple steatosis to nonalcoholic steatohepatitis, 
NASH, possibly leading to fibrosis, cirrhosis and hepatocellular carcinoma. The 
pathophysiology leading to NAFLD, and especially to hepatocellular damage after TG 
accumulation, is not yet fully understood. A “two hit” theory has been proposed to cause the 
NAFLD, the first being the accumulation of fat leading to steatosis, and the second being the 
oxidative stress due to ?-oxidation of fatty acids. Oxidative stress produces lipid peroxidation, 
to which the steatotic liver is believed to be vulnerable to, and results in NASH. It has been 
estimated, that 15-20% of patients with NAFLD develop NASH (273). 
 
The accumulated FFAs per se can be toxic to cells in non-adipose tissues. In the liver, this 
lipotoxicity enhances progression of liver injury. Studies have demonstrated  that liver injury 
and hepatic inflammation correlate with hepatocyte apoptosis. (280). FFAs contribute to 
apoptosis by activating both the intrinsic and the extrinsic apoptotic pathways (281,282). 
Saturated fatty acids (SFAs) have been shown to induce apoptosis in e.g. hepatocytes (283) 
and endothelial cells (284), and also monounsaturated fatty acids (MUFAs) are apoptotic, yet 
to a markedly lesser extent than SFAs (283).  
 
Even though the primary causes of NAFLD are obesity and insulin resistant state, also several 
other secondary causes may enhance NAFLD formation. Drugs (corticosteroids, synthetic 
estrogen, tamoxifen, etc.), surgical procedures (gastroplexy, extensive small bowel resection, 
jejuno-ileal bypass etc.), toxins (toxic mushrooms, petrochemicals, etc.), metabolic disorders 
(lipodystrophy, dysbetalipoproteinemia, acute fatty liver of pregnancy, etc.), and several other 
factors (HIV infection, small bowel diverticulosis with bacterial overgrowth, inflammatory 
bowel diseases, etc.) are associated with NAFLD (285,286).  
 
Fatty liver disease has been linked to many infections, including both periodontitis and C. 
pneumoniae. In healthy Japanese women, periodontitis associated with steatosis is illustrated 
by increased serum levels of aspartate aminotransferase (AST) and alanine aminotransferase 
(ALT) (287). Seropositivity to C. pneumoniae was significantly higher in men with non-
alcoholic steatohepatitis (288). In rats E. coli LPS and protease administration into gingival 
sulcus resulted in steatosis and hepatic inflammation (289). Also ligature-induced 
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periodontitis in rats induced hepatocytic lipid droplet formation (290). Thus these non-hepatic 
infections may play a crucial role also in the liver function. 
 
1.3.3. Steatosis and atherosclerosis 
 
Non-alcoholic fatty liver disease is associated with many features of metabolic syndrome 
(MetS), such as abdominal obesity, insulin resistance, dyslipidaemia, hypertension, and type 2 
diabetes, and can therefore be considered as the hepatic manifestation of MetS (291). Insulin 
resistance, irrespective of obesity, associates with NAFLD, and is also a risk factor for CVD 
(292). Epidemiological studies have postulated a link between NAFLD and other non-
classical CVD risk factors. These include decreased plasma/serum adiponectin concentrations 
(293-295), endothelial dysfunction (296), high plasma markers of lipid peroxidation 
(297,298), and inflammation (299,300). Also the hepatic synthesis of apoB-100, the rate-
limiting step of VLDL production and export, is reduced and may result in the retention of 
lipids in the hepatocytes. The abnormal assembly of VLDL is an important factor in the 
development of NAFLD, and leads to increased concentration of triglyceride- and cholesterol-
rich remnant particles that are atherogenic. (301) A link between these non-classical risk 
factors for CVD and NAFLD appears to be independent of insulin resistance or other MetS 
components. 
 
NAFLD is clearly associated with markers of subclinical atherosclerosis. Patients with 
NAFLD have significantly greater carotid artery IMT and higher prevalence of carotid 
atherosclerotic plaques than controls, even as early as in childhood (302-306). Most 
importantly, the positive correlation of the severity of NAFLD and IMT is independent of 
classical  CVD  risk  factors,  insulin  resistance  or  other  MetS  components  (307).  Another  
marker of subclinical atherosclerosis, endothelial dysfunction, also associates with NAFLD as 
well as the progression of NAFLD (296). A study on type 2 diabetics show a correlation 
between elevated liver enzyme levels and impaired endothelial function (308). Several studies 
have presented the connection between NAFLD and existing or future CVD event. The total 
mortality as well as the mortality to CVD-related incidences is higher in the NAFLD patients 
than in the general population. (309-311)  
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Even though the exact biological mechanisms, how NAFLD possesses a risk for CVD, are not 
yet fully understood, some common factors for these two diseases have been proposed. Such 
are oxidative stress, decreased levels of adiponectin, insulin resistance, increased levels of 
CRP, and inflammation. Abdominal visceral fat may secrete proinflammatory cytokines, a 
risk factor for both NAFLD and CVD. (311) Macrophages of adipose tissue may be a source 
of cytokines that induce the hepatic expression of SAA, or adipocytes may secrete SAA 
directly (312-314). Altogether the above mentioned data suggest a clear association between 
NAFLD  and  CVD,  or  that  NAFLD  may  be  a  risk  factor  for  early  development  of  
atherosclerosis. 
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1.4. Matrix metalloproteinases 
 
1.4.1. Introduction 
 
Matrix metalloproteinases are zinc-dependent enzymes that degrade all components of ECM 
and basement membrane (BM). MMPs belong to endopeptidases as they cleave the internal 
peptide bond, and thus far, over 20 MMPs have been identified. The degradation of ECM is 
essential in normal physiology, such as embryonic development, wound healing, and cell 
migration (315). However, MMPs are also expressed in several pathological conditions, e.g. 
in tumour metastasis (316), CVD (317), periodontitis (318) and rheumatoid arthritis (319). 
MMPs  are  crucial  molecules  of  inflammatory  cells,  as  they  can  remodel  the  ECM  thereby  
facilitating the leukocyte traffic through tissues, such as basement membrane during 
inflammation (320). Several studies imply that MMPs participate in the rupture of 
atherosclerotic plaque thereby promoting formation of acute coronary syndrome (ACS). 
 
There are six groups of MMPs: collagenases, gelatinases, stromelysins, matrilysins, 
membrane-type matrix metalloproteinases (MT-MMPs), and other MMPs, and they exist as 
two types, secretory MMPs and membrane-bound MMPs. Collagenases, such as MMP-1 and 
MMP-8, initiate the cleavage of triple helical collagens I, II, and III (321). Gelatinases, like 
MMP-2 and MMP-9, cleave e.g. native type IV, V, VII, and X collagens and elastin, as well 
as the proteolytic products of collagens deriving from types I, II, and III after the initial 
cleavage by collagenases (322). 
 
MMP activity is regulated at the transcription, posttranslational activation, and interaction 
with inhibitors, the level of transcription being the main level of regulation. Activation of 
transcription is stimulated by inflammatory cytokines such as TNF-? and IL-1? (47,323), 
hormones (324), and growth factors (325). The upregulation MMP-9 can be induced by C. 
pneumoniae HSP60 (326), and by ox-LDL (327) whereas e.g. MMP-8 is inducible by CD40L 
(41).  
 
Most MMPs are synthesized and secreted as inactive pro-enzymes, zymogens, and the 
majority of MMPs have a pro-peptide that includes a highly conserved cysteine-containing 
sequence,  so  called  cysteine  switch.  This  switch  binds  zinc  in  the  catalytic  domain  thereby  
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keeping the enzyme inactive until the covalent bond between cysteine and Zn2+ is disrupted 
by proteolytic cleavage of the pro-peptide domain exposing the catalytic site. (328) Both 
MMP-8 and -9 are stored as zymogens in secretory granules of neutrophils and eosinophils 
(329). The activation of zymogens occurs either intracellularly, at the cell surface by MT-
MMPs, in the extracellular space by other proteases, or by activated MMPs (stepwise 
activation). The last holds for the activation of MMP-8 and -9, as e.g. MMP-3 is capable of 
activating both (330) whereas MMP-9 can also be activated by MMP-2, -7, and -13 
(331,332).  
 
In atherosclerotic lesions, MMP activity may result in the migration of vascular SMCs 
through the internal elastic lamina into the intimal space, where they proliferate thus 
contributing to the plaque formation (333). The fibrous cap of the atherosclerotic plaque is 
rich in collagen, especially types I and III, and the breakdown of the cap results in 
intraluminal thrombosis. MMPs secreted by macrophages are capable of degrading the cap 
collagen (334). MMPs localize especially to the shoulder regions of the plaque (47,335), the 
most vulnerable area of the cap. Increased MMP production by foam cells correlates with a 
thinned fibrous cap (47,336). 
 
The activity of MMPs is inhibited endogenously by specific tissue inhibitors of 
metalloproteinases (TIMPs) and by non-specific inhibitors, such as ?2-macroglobulin, a 
serum protease inhibitor that is abundant in the extracellular space and may therefore have an 
important role in the overall MMP activity in tissues (337). TIMPs inhibit the activity of 
MMPs by binding to the zinc-binding site of active MMPs at molar equivalence (338). To 
date, four members of the TIMP gene family have been identified, TIMP-1, -2, -3, and -4, that 
have 30-40% amino acid identity. TIMP-1, -2, and -4 are secreted in soluble form, whereas 
TIMP-3 in associated with ECM. TIMP-1 and -2 are capable of inhibiting the activity of most 
MMPs, and they can form complexes with inactive MMPs. TIMPs are produced by many cell 
types, such as fibroblasts and endothelial cells. The expression of e.g. TIMP-1 is regulated at 
the level of transcription by growth factors, cytokines and hormones. TIMPs are not only 
inhibitors of MMPs but they also have other functions in cell morphology, stimulation of cell 
growth of different cell types, steroidogenesis, and germ cell development. (339) 
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1.4.2. MMP-8 and -9 in atherosclerosis 
 
1.4.2.1. MMP-8 
 
Several studies indicate a role of MMP-8, also known as collagenase-2 or neutrophil 
collagenase, in atherosclerosis. In human plaques, MMP-8 protein and mRNA co-localize 
with macrophages (340), and their aortic concentration is elevated in patients with abdominal 
aorta aneurysm (AAA) (341) and ruptured AAA (342). Increased MMP-8 may reflect the 
state of the disease as its activity is higher in patients with plaque progression (343), and 
plaques prone to rupture contain more immunoreactive MMP-8 than stable lesions (335). 
Also a few studies using serum or plasma samples give similar indications; in patients the 
presence and severity of CAD (344), as well as carotid artery plaque progression (343) are 
related to elevated MMP-8 concentrations. The concentration of MMP-8 has been reported to 
be decreased in acute disease progression/end state such as in patients with heart failure (345) 
or cerebral ischemia (346). MMP-8 pro-enzyme is stored in granules of mature neutrophils - 
the cells that are first to arrive to the inflammatory site (347). Therefore MMP-8 is released at 
the initial stage of inflammation and may thus participate also in atherogenesis. 
 
1.4.2.2. MMP-9 
 
Compared to MMP-8, more research has been focused on the role of MMP-9 in CVD. MMP-
9 (92-kDa gelatinase or gelatinase-B) is essential for SMC migration (348,349). The cells of 
the inflamed atherosclerotic plaque, such as macrophages, SMCs, and endothelial cells, are 
able to produce MMP-9 (45,350). It has been shown both in animals and humans that lipid 
lowering may reduce expression and activity of MMP-9 likely due to reduced macrophage 
accumulation (351-353). High serum or plasma MMP-9 concentrations have been reported in 
patients with unstable angina, AMI (354,355), a history of MI (356,357), unstable coronary 
plaques (358), and congestive heart failure (345). MMP-9 is highly expressed in the 
vulnerable regions of atherosclerotic plaques (45), in unstable carotid (359), and coronary 
plaques (358), in unstable angina (350), in AAA (360) as well as in ruptured AAA (342). In 
apoE-/--mice, overexpression of active MMP-9 in the macrophages of advanced aterosclerotic 
lesions causes plaque disruption (361). In a hypertensive rat model, MMP-9 also promotes the 
progression of cerebral aneurysm (362). Crossing apoE-/- mice with MMP-9 deficient mice 
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results in reduced number of lesions and lipid accumulation in aorta as well as decreased 
lesion macrophage content and media destruction (363). A prognostic significance of plasma 
MMP-9 was shown by Blankenberg et al., as high baseline MMP-9 level in CAD patients 
predicted cardiovascular mortality in a four-year follow-up (364). In patients with ?50% 
carotid stenosis, increased plasma MMP-9 associated with a 2-fold risk for cardiovascular 
death in a follow up of over four years (365). These factors clearly indicate the important role 
of MMP-9 in the progression of CVD. 
 
1.4.3. TIMP-1 in atherosclerosis 
 
The balance between MMPs and TIMPs is believed to be crucial in the development and 
progression of atherosclerosis as it can e.g. block SMC migration by inhibiting MMP-activity 
(334,366,367). In humans, increased TIMP-1 concentrations or expression have been 
observed in several forms of CVD. For example patients with ACS and MI have high plasma 
TIMP-1 concentration, it is upregulated in AAA, and serum TIMP-1 associates with the 
presence of carotid lesions (355,360,368,369). The predictive value of TIMP-1 for 
cardiovascular death has been shown in patients with suspected CAD with a follow-up of 2.6 
± 1.2 years (370). Several animal studies have shown the importance of TIMP-1 in the 
prevention of the atherosclerotic lesion development. In apoE-/- mice, over-expression of 
TIMP-1 reduces lesions (371). In apoE/TIMP-1-double-knockout mice again, the plaque size 
reduced and the aneurysm formation, MMP activity, as well as macrophage lipid 
accumulation increased in the lesions (372). However, study from Lemaitre et al. showed no 
difference in the lesion size or content of collagen and macrophages in the lesions of the 
apoE-/-/TIMP-1-/- mice compared to the apoE-/- mice, but the mice exhibited increased pseudo-
microaneurysms together with high macrophage content in the media (373). Lipid lowering 
therapy increases TIMP-1 in carotid plaques further strengthening the conception of a 
protective role of TIMP-1 in CVD (353). 
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2. AIMS OF THE STUDY 
 
1. To investigate the effect of A. actinomycetemcomitans and C. pneumoniae infections on 
atherosclerotic parameters. 
 
2. To investigate the effect of A. actinomycetemcomitans and C. pneumoniae infections on 
the liver. 
 
3. To evaluate the association of serum MMP-8 and TIMP-1 concentrations and CVD events 
in a population-based cohort with a follow-up time of 10 years. 
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3. MATERIALS AND METHODS 
 
Materials 
 
Animal studies (I, II, III) 
Male apoE-/- mice (Charles River Laboratories, Belgium) were fed a regular mouse chow and 
kept in germ-free environment. The experiments were conducted in conformity with the 
Finnish regulations, and the protocols were approved by The Animal Care and Use 
Committee of the National Public Health Institute, Helsinki, Finland. 
 
Human subjects (IV) 
Altogether 2682 Finnish men were enrolled in the Kuopio Ischemic Heart Disease Risk 
Factor (KIHD) study between 1984 and 1989, and data on their socioeconomic status were 
collected at the time of sampling. The study was approved by the Research Ethics Committee 
of the University of Kuopio, Kuopio, Finland, and all subjects gave their written informed 
consent. 
 
Methods 
 
Method Publication 
Culture and administration of Actinobacillus actinomycetemcomitans I, II, III 
Culture and administration of Chlamydia pneumoniae II, III 
En face morphometric analyses of aortas, Sudan IV staining of lipids I 
Aortic cryosections I, II 
Oil Red O lipid staining of cryosections (aorta, liver) I, II, III 
MMP-8 staining of aortic cryosections I 
MMP-9 staining of aortic cryosections I, II 
CD68 staining of aortic cryosections I 
Serum cholesterol concentration I, II, III, IV 
Serum triglycerides concentration I, II, III, IV 
Serum apoA-I concentration I, II, III 
Serum PLTP activity I, II, III 
Serum LPS activity I, II, III 
Serum A. actinomycetemcomitans IgA and/or IgG concentrations 
(ELISA) 
I, III IV 
Mouse CRP concentration I 
Serum LBP concentration I, III 
Mouse pro-MMP-9 concentration I 
Zymography of serum MMP-9  I 
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Serum lipoprotein profiles I  
Lipoprotein isolation I 
Phospholipid concentration of lipoprotein fractions I 
Total protein concentration of lipoprotein fractions I 
SAA concentration II, III 
TNF-? concentration II 
sICAM concentration II 
sVCAM concentration II 
sE-selectin concentration II 
MPO staining of aortic cryosections II 
Acetylation of LDL II 
[3H]-cholesteryl oleate labelling of ac-LDL II 
Mouse peritoneal macrophage cholesterol uptake II 
Mouse peritoneal macrophage cholesterol efflux II 
HE-staining of paraffin sections III 
Steatosis and inflammation grading of liver paraffin sections III 
Liver lipid (PL, cholesterol, TG) analyses III 
Liver fatty acid analysis III 
Tissue RNA isolation III 
cDNA synthetization III 
qPCR III 
Serum ALT concentration III 
Serum adiponectin concentration III 
Serum non-esterified fatty acid concentration III 
Serum phospholipid concentration III 
Endothelial function measurement II 
Plasma fibrinogen concentration IV 
Serum MMP-8 concentration (IFMA) IV 
Serum TIMP-1 concentration (ELISA) IV 
Statistical analyses I, II, III, IV 
 
 
Study design (I, II, III) 
In publication I, 10 mice were divided into three groups, 3-4 mice/group, and were given 
weekly A. actinomycetemcomitans injections for 4, 6, or 8 weeks. Corresponding control 
groups received vehicle. All mice were killed one week after their last injection. 
 
For publications II and III, a total 59 mice were used. For the short, 14-week experiment, 20 
mice were divided into three groups. Group one was inoculated with C. pneumoniae strain 
Kajaani 7 once (acute infection), group two received three inoculations (chronic infection), 
and the control group received vehicle. In the longer, 24-week experiment, 39 mice formed 
four groups, of which group one received weekly A. actinomycetemcomitans injections, group 
two was inoculated intranasally three times with C. pneumoniae, group three received both 
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infections, and group four received vehicle. The intervals of inoculations are depicted in the 
table below. 
 
Cholesterol uptake and efflux experiments (II) 
The efflux capacity of peritoneal macrophages of the mice was measured. Macrophages from 
each mouse were cultured overnight and the conditioned media were collected after which 
they were cultured with [3H]-cholesteryl oleate -labelled acetylated LDL (ac-LDL) for 24 
hours. After equilibrating the cells overnight in fresh media, the cells were incubated with 
(ABCA1-mediated efflux) and without (spontaneous efflux) human apoA-I for 5 hours. 
Radioactivity  was  measured  from  the  media  and  from  the  cell  lysates.  The  efflux  was  
calculated as a percentage of the activity in the medium from the total activity found in the 
well per protein (µg/ml). The uptake was measured directly from the cell lysates. 
 
The ability of the sera of the infected mice to function as cholesterol acceptors was measured 
by loading RAW264.7 cells with ac-LDL as previously described, followed by a 5-hour 
incubation with or without 2% serum isolated from each mouse. The acceptance of free 
cholesterol by the mouse sera was measured by labelling RAW264.7 cells with [3H]-
cholesterol with the same incubation time and serum concentration as above. 
 
Endothelial function test (II) 
We tested how macrophages of infected animals affect blood vessels systemically. We 
isolated peritoneal macrophages from each mouse and cultured them overnight. Conditioned 
media were collected and a 500 µl pool of each study group was formed. Rat superior 
mesenteric artery pieces were incubated in these pools in +37ºC for 30 minutes, and 
approximately 5 mm long pieces (6-8 pieces/group) were placed in organ bath chambers. The 
function of endothelium was determined by precontraction with phenylephrine followed by 
acetyl choline induced relaxation. The actual experiments were performed twice by 
contracting the vessels with phenylephrine (1 x 10-6 mmol/l) and thereafter inducing 
cumulative relaxation with acetylcholine (1 x 10-10 –  1  x  10-5 mmol/l). Finally, the vessels 
were contracted with phenylephrine followed by 10-minute HDL-induced (10 µg/ml) 
relaxation. 
 
 
Table. Timetable of the mouse studies in publications II and III. 
 
  Age (weeks) 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 
Group 14 week 
Acute 
Cpn     ? †         
 
  
  Chronic Cpn ?  ?  ? †           
  Control ?  ?  ? †           
 24 week A.a.      ?? ?? ?? ?? ?? ?? ?? ?? ?? ? † 
  Cpn ?  ?  ?           † 
  A.a.+Cpn ?  ?  ? ?? ?? ?? ?? ?? ?? ?? ?? ?? ? † 
  Control (vehicle) ?  ?  ? ?? ?? ?? ?? ?? ?? ?? ?? ?? ? † 
 
Cpn, Chlamydia pneumoniae 
Aa, Aggregatibacter actinomycetemcomitans 
?, C. pneumoniae inoculation 
?, A. actinomycetemcomitans inoculation 
???, Vehicle inoculation 
†, sacrifice 
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4. RESULTS AND DISCUSSION 
 
4.1. ApoE-/- mouse studies; the effect of A. actinomycetemcomitans and C. 
pneumoniae on atherosclerosis-related parameters and the liver 
 
In the original publications I, II, and III, mice were given A. actinomycetemcomitans and/or 
C. pneumoniae, and their effects on various parameters associated with atherogenesis and 
liver characteristics were determined. Hearts, aortas, livers, lungs, sera, and peritoneal 
macrophages were collected. 
 
4.1.1. A. actinomycetemcomitans -induced changes in atherosclerosis-related 
parameters 
 
Inflammatory markers (I, II) 
In publications I and II, several atheorsclerosis-associated inflammatory markers were 
measured. Of these, serum LPS activity (II) as well as CRP (I), SAA (II), and TNF-? (II) 
concentrations were clearly elevated in the infected mice compared to the controls. In 
publication I, serum LPS activity had an increased trend in the infected mice. The 
histochemistry of aortic sinus showed an increased trend of CD68 (I) and neutral lipid content 
(I) whereas MMP-9 was either significantly (I) or non-significantly (II) increased in the aortic 
sinuses of the infected mice compared to the controls. This is in accordance with the overall 
serum MMP-9 activity, as measured with zymography (I), which was higher in the infected 
groups. 
 
Narrowing of arteries is not a necessary marker of forthcoming complications, since half of 
the infarctions occur in arteries with <50% stenosis. Therefore, the treatment should not 
solely focus on this factor, but also on inflammation, which is the main feature of ruptured 
plaque. The basic methods for combating CVD risk factors, such as exercise, low-cholesterol 
diet, smoking cessation, and statins, all have also effects on the total inflammatory status of 
the body (374). Inflammatory markers, such as CRP, SAA, fibrinogen, and TNF-?, have 
become more and more used when predicting possible CVD risks and events. Our results 
show that i.v. -administered A. actinomycetemcomitans mimicking the bacteraemia in 
periodontitis, can induce expression of atherosclerosis-related inflammatory markers 
indicating the possible proatherogenic effect of periodontal infection. The observed increase 
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in  MMP-9  is  in  accordance  with  earlier  studies  showing  its  role  in  the  development  of  
atherosclerosis in apoE-/- mice (363,375) as well as CVD in humans (350,355,358,359,376). 
MMP-9 localizes in the shoulder regions of atherosclerotic plaques, the sites prone to rupture, 
where also inflammatory cells, such as macrophages, accumulate. Activated macrophages are 
able to secrete MMP-9 (350), and the secretion can be incuded by TNF-? and LPS (46,377). 
The increase in TNF-? and LPS concentrations in our study may have further enhanced 
MMP-9 production. Another inducer of MMP-9 production in monocytes is modified LDL 
such as enzymatically degraded LDL and ox-LDL (327,378). In publication I, LDL 
modification was detected (see “Lipoprotein analyses and aortic lipid accumulation”). The 
proatherogenic properties of MMP-9 also include potential of processing proinflammatory IL-
?? from its precursor (379) and induction of vascular SMC proliferation and migration (333). 
 
Our results are in accordance with earlier studies on another periodontal pathogen, P. 
gingivalis, showing that oral infection of apoE-/- and intravenous injections of apoE+/- mice 
accelerated atherogenesis and induced host response (138,139,380). The increased SAA 
concentration indicates proatherogenic changes, as in addition to its HDL modifying 
properties, it has been suggested to induce retention of HDL in the arterial wall via binding to 
proteoglycans (381). All these results indicate an association between A. 
actinomycetemcomitans -infection and inflammatory changes in apoE-/- mouse model. These 
data indicate that the direct access of periodontal pathogens to the systemic circulation 
increases atherosclerosis-related inflammatory markers and may be regarded as one of the 
infections associated with CVD development. 
 
Lipoprotein analyses and aortic lipid accumulation (I) 
In publication I a significant increase in serum cholesterol and TG concentrations were seen 
in the experimental group, which received 8 injections of A. actinomycetemcomitans. In 
addition, the lipoprotein profile demonstrated a shift toward smaller VLDL+IDL and HDL 
particle sizes with increased cholesterol concentrations. However, en face analysis of the 
whole aorta did not show clear difference in lipid accumulation between the groups. The 
infected mice showed increased protein and LPS content in VLDL and LDL fractions. The 
increased protein content reflects a possible decreased particle size; indeed, this was detected 
in the lipoprotein profile analyses. As all lipoprotein classes, especially HDL, participate in 
the  clearance  of  LPS,  and  as  in  this  study  there  were  no  differences  in  LPS contents  of  the  
HDL fractions, it can be assumed that the excess LPS administered was addressed to VLDL 
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and LDL fractions. No differences were observed in cholesterol and TG concentrations in the 
experiments of publication II, which may be due to the different study design. 
 
The alterations seen in study I have been shown in humans during acute phase response (244). 
The change in HDL subclass distribution may be a result of e.g. slightly increased PLTP 
activity which was observed in study I. (247,382) A. actinomycetemcomitans infection 
appears to result in proatherogenic lipid composition, namely decreased VLDL and LDL 
sizes. (111,383) Also the change in HDL size may affect atherosclerosis formation as even 
though small HDL particles can function as cholesterol acceptors in reverse cholesterol 
transport, larger HDL particles have higher efflux capacity and thus are considered more anti-
atherogenic (384).  
 
Endothelial function (II) 
We isolated and cultured peritoneal macrophages of each infected mouse. For endothelial 
function tests, conditioned medium pools of cultured peritoneal macrophages from each 
infected mouse group and controls were formed. We mimicked a vessel response to activated 
macrophages by incubating pieces of rat superior mesenteric arteries in these medium pools. 
The endothelial function of the vessels was determined thereafter in an organ bath chamber. 
The ability of HDL was significantly better to relax the vessel incubated in the pool of 
conditioned media of the A. actinomycetemcomitans group compared to the medium pool of 
the control group indicating improved endothelial function. Interestingly, the relaxation curve 
of the infected group vs. the control group showed enhanced relaxation trend also with acetyl 
choline.  In  addition,  at  the  acetyl  choline  concentrations  of  3.3x10-9 and 1x10-8 mmol/l the 
difference in relaxation was significant. 
 
To our knowledge, there are no previous studies demonstrating how directly administrated A. 
actinomycetemcomitans or A. actinomycetemcomitans activated macrophages affect 
endothelial function. From periodontal pathogens, oral challenge of P. gingivalis increases 
aortic VCAM-1 expression in apoE-/- mice  (139)  indicating  that  oral  bacteria  can  affect  
endothelial function. This may happen by e.g. invading endothelial cells as has been shown 
with P. gingivalis (66). Periodontitis patients show impaired endothelial function compared to 
healthy controls, and treatment of periodontitis improves the function (104,270,385-387).  
However, in our study, no significant changes were observed in serum sVCAM-1, sICAM-1, 
or sE-selectin in the A. actinomycetemcomitans -infected mice, and the relaxation studies 
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showed improved endothelial function, which is contradictory to earlier studies and further 
studies are needed to verify the results.  
 
Cholesterol  uptake and efflux studies (II) 
The cholesterol uptake and efflux of peritoneal macrophages as well as the efflux capacity of 
sera isolated from infected mice were measured. The cholesterol uptake by the peritoneal 
macrophages of the A. actinomycetemcomitans mice was significantly elevated compared to 
the control group. The ABCA1-mediated efflux was non-significantly impaired, whereas no 
differences  were  seen  in  spontaneous  efflux.  The  efflux  ability  of  sera  of  the  infected  mice  
showed no remarkable differences compared to the controls. 
 
The expression of SR-A is increased in infections (77), thereby increasing the uptake of 
modified LDL. ABCA1 expression is decreased upon macrophage stimulation with LPS or 
e.g. TNF-? thereby reducing the efflux (75). As in our study both LPS and TNF-? 
concentrations were significantly increased in the A. actinomycetemcomitans -infected mice, 
the observed trend to reduced efflux from the peritoneal macrophages may well be 
attributable to these factors, whereas the increased uptake most likely is a result of increased 
SR-A expression. Unfortunately, we did not have the possibility to determine the macrophage 
ribonucleic acic (RNA) expression levels of these receptors. 
 
4.1.2. C. pneumoniae -induced changes in atherosclerosis-related parameters 
 
Inflammatory markers (II) 
Chronic C. pneumoniae infection of the 14-week study increased serum LPS activity (ns.) and 
SAA concentration which was significantly elevated in the group with acute infection. 
Immunohistochemical staining of the aortic sinus showed increased MMP-9 expression in the 
acute group. 
 
The data show that acute C. pneumoniae infection results in acute phase response depicted by 
elevated serum SAA levels and a slight increase in LPS activity. This is in accordance with 
earlier studies, since even though the biological activity of cLPS is lower than that of 
enterobacterial LPS, it still induces cytokine production and immune responses (388). The 
elevation of MMP-expression by C. pneumoniae has also been shown in in vitro studies with 
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mouse peritoneal macrophages (326). This supports a study in which C. pneumoniae -
infection accelerated atherosclerosis progression in apoE-/- mice  (159).  In  a  LDLr-/-/apoE-/- 
double knock-out mouse model, C. pneumoniae increased MMP-9 immunoreactivity in aortic 
arch (389), which is in accordance to our results of the aortic sinus. Like in A. 
actinomycetemcomitans -infected mice, C. pneumoniae induces expression of acute phase 
markers that have been shown to be linked to atherosclerosis.  
 
Lipoprotein analyses (II) 
Acute infection with C. pneumoniae increased serum PLTP activity, but no differences were 
seen in serum cholesterol or TG concentrations.  
 
Infections cause increased TG concentrations in humans (390) but again no differences were 
observed in C. pneumoniae -infected mice in our study. The fact that we did not detect 
changes in cholesterol concentrations is similar to the results of an earlier study on apoE-/- 
mice with chronic C. pneumoniae infection  (159).  Similarly,  a  six-month  study  with  C. 
pneumoniae inoculation twice a week resulted in a significant increase in atherosclerotic 
lesion areas in LDLr-/- mice fed a high cholesterol diet, but no differences were detected in 
total cholesterol concentrations (161). The ability of C. pneumoniae to induce atherosclerosis 
seems to require high serum cholesterol concentration (162,164), which is naturally more 
elevated in apoE-/- mice than in LDLr-/- mice on normal chow diet. Without hyperlipidemia, 
C. pneumoniae causes only an inflammatory response (167). The acute infection increased 
PLTP activity similarly as was observed in study I in the mice infected with A. 
actinomycetemcomitans. Therefore it seems likely that in these mice, PLTP activity is 
increased due to acute phase response as has also been observed in humans (247,391), but 
normalizes when the infection has become chronic. In NIH/S mice again, acute C. 
pneumoniae infection did not result in significant changes in the serum PLTP activity (392). 
 
Endothelial function (II) 
In the 14-week study, both sICAM and sVCAM concentrations were significantly higher in 
the chronic as well as in the acute infections, and the HDL-mediated relaxation of the vessels 
was clearly impaired in these groups. According to Tukey’s Multiple Comparison Test, 
incubation in the macrophage medium of the chronic infection group (14-week study) 
significantly decreased the ability of acetyl choline to relax the incubated vessel. The 
difference was significant at the acetyl choline concentration of 3.3.x10-8 mmol/l. In the 24-
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week study, a similar trend as in A. actinomycetemcomitans group was observed in the acetyl 
choline induced relaxation curve. Also HDL-induced relaxation showed improved endothelial 
function in this C. pneumoniae group of the 24 week study.  
 
C pneumoniae has been shown to impair endothelial function possibly by hampering 
endothelial NO production. It also induces VCAM-1 expression in apoE-/- mice (393,394) 
most likely due to the ability of the pathogen to invade and multiply in endothelial cells 
(79,170). Relevant to our experiment are the results showing that C. pneumoniae is  able  to  
infect and systemically spread via macrophages (395) thus likely inducing expression of 
inflammatory mediators that may affect the endothelial function. As in our 14-week study 
HDL had impaired ability to relax the vessels and the relaxation capability of acetyl choline 
was reduced, the results indicate a direct role of this infection in NO availability and 
endothelial dysfunction. However, the impact of acute infection seems to be more profound as 
there were no similar changes in the chronic C. pneumoniae group of the 24-week study. This 
is further supported by a study conducted in pigs showing that acute C. pneumoniae infection 
causes endothelial dysfunction (396). The induced production of VCAM-1 in the C. 
pneumoniae -infected mice compared to E-selectin in animals with dual infection (A. 
actinomycetemcomitans and C. pneumoniae)  may  reflect  a  slightly  different  response:  E-
selectin preferentially recruits Th1 cells whereas VCAM-1 is rather involved in Th2 cell 
recruitment (397). 
 
Cholesterol uptake and efflux studies (II) 
The cholesterol uptake by the peritoneal macrophages isolated from the C. pneumoniae -
infected mice showed no differences compared to the controls. Spontaneous efflux was 
significantly higher in all C. pneumoniae –infected groups. An opposite but a non-significant 
trend was observed in the ABCA1-mediated efflux. The efflux capacity of the sera isolated 
from these mice was slightly lower (n.s.) in both chronic groups compared to their controls. 
 
The increased spontaneous efflux may be a result of increased diffusion or activity of SR-BI, 
but  their  role  in  our  experiments  needs  further  studies.  As  the  sera  from  the  mice  with  the  
chronic C. pneumoniae could not function properly as cholesterol acceptors, we may 
hypothesize that in these mice the function of HDL is impaired due to its inflammation-
related modifications. As previously demonstrated during infection, HDL concentration 
decreases, its composition changes, and its efflux capacity decreases (112).  
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4.1.3. A combined A. actinomycetemcomitans and C. pneumoniae infection -
induced changes in atherosclerosis-related parameters 
 
Inflammatory markers (II) 
The dual infection elevated serum LPS activity as well as TNF-? and SAA concentration, but 
the results did not reach statistical significance. The immunohistological stainings of MMP-9 
and MPO in the aortic sinus showed increased immunoreactivity. 
 
As outlined above, dual infection evoked an inflammatory response as demonstrated by the 
increased concentrations of inflammatory markers compared to mice with single infection. 
This is the only group with elevated MPO production in the aortic sinus indicating that the 
infectious burden may impair the function of HDL in cholesterol efflux by increasing MPO, 
an HDL-oxidizing enzyme (230,398), production in atherosclerosis-prone areas.  
 
Endothelial function (II) 
From endothelial function markers, serum sE-selectin concentration was significantly 
increased in the group of combined infections. In relaxation experiments, the study group had 
clearly reduced HDL-mediated relaxation of the vessel compared to the control group. A 
similar effect was observed in acetyl choline induced relaxation curve with a significant 
difference at the concentrations of 1x10-9, 3.3x10-9, and 1x10-8 mmol/l. 
 
The co-infection had an effect on the endothelial function as seen in the increase of serum sE-
selectin concentration and reduction of both acetyl choline and HDL-induced relaxations of 
the rat vessels. These results are in accordance to a study where Liuba et al co-infected apoE-/- 
mice with C. pneumoniae and Helicobacter pylori (394). A serological study has also shown 
the pathogen burden to be an independent predictor of endothelial dysfunction (265). As HDL 
was not able to induce relaxation of the vessels, this indicates that the factors secreted by 
inflammatory cells directly affect the endothelium and thus promotes functions related to 
early atherosclerosis formation, i.e. endothelial dysfunctions. Therefore it is possible that the 
actual infection site is not necessarily present in the vasculature but affects systemically - as 
could be the case in periodontitis. Endothelial activation can be induced by e.g. LPS, bacteria, 
and TNF-?, leading to a release of pro-inflammatory cytokines by endothelial cells. They may 
also down-regulate SR-BI, which mediates HDL-induced relaxation (399). In diseased 
endothelium, the synthesis and bioactivity of vasodilators, such as NO, is reduced leading to 
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redox imbalance. Increased ROS production enhances NO degradation, thus making the 
endothelium more dysfunctional and leading to increased adhesion of inflammatory cells and 
SMC proliferation (253). There are several studies that have assessed the relationship between 
endothelial function and inflammation markers such as CRP, sVCAM-1, and sICAM-1, 
showing mainly inverse correlation (reviewed in (266)). Our results indicate that the dual 
infection with A. actinomycetemcomitans and C. pneumoniae induces endothelial dysfunction, 
probably also via increased TNF-? production promoted by the challenge of LPS. 
 
Cholesterol uptake and efflux studies (II) 
The cholesterol uptake by the macrophages of the group with combined infection was slightly 
elevated. Of efflux studies, spontaneous efflux showed a significant increase compared to the 
control  group.  The  efflux  capacity  of  the  sera  in  this  group,  however,  was  significantly  
decreased. 
 
This is the only group with a decreased efflux capacity of the sera indicating that the HDL has 
been modified making it less able to accept cholesterol. The dual infection therefore affects 
HDL’s ability to remove excess cholesterol in reverse cholesterol transport thereby promoting 
atherosclerosis formation. 
 
4.1.4. A. actinomycetemcomitans and C. pneumoniae infection -induced changes 
in the liver 
 
4.1.4.1. The effect of A. actinomycetemcomitans on the liver (III) 
 
Administration of A. actinomycetemcomitans induced moderate liver inflammation with 
inflammatory cell infiltration. A. actinomycetemcomitans was detected by PCR in the livers of 
30% of the mice infected with A. actinomycetemcomitans. Liver phospholipid concentration 
was decreased, which was also reflected in the increased liver TG/PL ratio. These changes 
may result from increased liver phospholipase A1 and A2 activities, which are induced by 
LPS (400). No changes were detected in liver TG or cholesterol concentrations, nor in 
unsaturated or saturated fatty acid proportions compared to the controls. Only anti-
inflammatory dihomo ?-linoleic acid (DGLA) showed a relative increase in the infected 
group. DGLA may be considered anti-inflammatory as it decreases the pro-inflammatory 
effects of arachidonic acid (ARA) (401). Expression studies showed elevated expression of 
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inflammatory markers IL-1? and CD68, a macrophage marker, as well as MCP-1 and FAS. 
Periodontitis has been linked to liver inflammation in animal models (290), which is in 
accordance to our results. Altogether the association between periodontitis and liver 
alterations has been scarcely studied. Our results indicate that constant exposure to A. 
actinomycetemcomitans causes inflammatory response in the liver as demonstrated by 
histology and expression studies.  
 
4.1.4.2. The effect of C. pneumoniae on the liver (III) 
 
C. pneumoniae was detected in the lungs (100% and 55%) and livers (21% and 0%) of the 
infected mice of the 14-week and 24-week studies, respectively. Chronic infection resulted in 
hepatic microvesicular appearance (14-week and 24-week study) and promoted liver 
inflammation (24-week study). Liver phospholipid concentrations were significantly 
decreased in all C. pneumoniae infected groups, but no changes were detected in liver TG and 
cholesterol concentrations. The only exception was the decreased TG concentration in the 
acute group compared to the control. The livers in the acute group were also depleted of lipids 
as was shown with lipid staining. The TG/PL ratio was lower in the acute C. pneumoniae 
group and higher in both chronic C. pneumoniae groups compared to the controls.  
 
Hepatic saturated fatty acid content was clearly increased in acute infection, but decreased in 
chronic infections, especially in the 24-week study. Of unsaturated fatty acids, acute infection 
resulted in reduced MUFA content, whereas chronic infection increased the proportion of 
monounsaturated with a concomitant decrease of polyunsaturated fatty acids (PUFA). In the 
14-week study, chronic infection increased DGLA proportion, and its precursor, ?-linoleic 
acid (GLA), was correspondingly decreased in both acute and chronic infections. Acute 
infection elevated the levels of both anti-inflammatory n-3 PUFA and pro-inflammatory 
ARA. Arachidonic acid is considered pro-inflammatory since it is a substrate for pro-
inflammatory eicosanoids (401). In expression studies, hepatic expression of IL-1?, CD68, 
and MCP-1 were induced in acute group, but no differences were observed in chronic groups 
except for the slight decrease of IL-1? expression detected in the 14-week study. 
 
In the chronic group of the 14-week study, the observed high proportions of MUFA and 
distinct hepatic fatty acid profile compared to both the control as well as to the acute infection 
group indicate an effect of the duration of the infection. The acute group had more 
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inflammatory changes as was seen in the alterations in the expression studies and e.g. in the 
proportions of hepatic pro-inflammatory ARA as well as in anti-inflammatory n-3 fatty acids. 
Altogether, the hepatic fatty acid profile was similar in both chronic groups and differed 
clearly from that of the acute group.  
 
As has been shown, the liver plays a significant role in the defence against bacterial infection. 
(402) and e.g. C. pneumoniae is able to replicate and induce pro-inflammatory cytokine 
production in Kupffer cells, the liver macrophages (403). Of the fatty acids, hepatic n-3 
PUFAs have a protective role (404), and our study further enhances this view: n-3 PUFA and 
inflammation correlated negatively with each other. The observed clear reduction in PL 
concentrations in all infected groups may imply reduction in cell membrane PLs, as seen in 
mice infected with hepatitis virus (405). Results suggest that the course of C. pneumoniae -
induced liver response involves first inflammation (acute) followed by a FA imbalance 
observed in the chronic groups. The histological morphology suggested the presence of mild 
steatosis, but the lipid staining and expression studies did not support this concept. However, 
the observed microvesicular appearance and changed fatty acid profile indicate a hepatic 
response to these infections, but further studies are warranted to specify the findings.  
 
4.1.4.3. The effect of the combined infection with A. actinomycetemcomitans and C. 
pneumoniae on the liver (III) 
 
The dual infection resulted in liver inflammation and decreased PL concentration. There were 
no  significant  changes  in  liver  TG,  cholesterol,  SFA,  MUFA,  or  PUFA  concentrations  
compared to controls; only a slight increase in DGLA proportion was detected. Expression of 
IL-1? was increased, whereas MCP-1 was clearly downregulated. 
 
The effects of the two infections were not cumulative as contrary to what one could have 
hypothesized. The minor changes mainly in the inflammatory parameters observed indicate 
that the first infection with C. pneumoniae may have primed the mice and induced an 
immunological defence. This may have therefore resulted in the marginal differences in 
parameters observed after the second infection with A. actinomycetemcomitans.  
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4.2. Serum MMP-8, a risk factor for future CVD death 
 
Our study (IV) shows that elevated serum MMP-8 concentration in a 10-year follow-up is an 
independent risk factor for AMI, CHD, CVD, and all cause death. Especially men with 
subclinical atherosclerosis (IMT > 1 mm) had a three-fold increased risk for CVD death 
independently of other risk factors. With increased MMP/TIMP-1 ratio the risk was close to 
2.5-fold, but only of borderline significance in the multivariate model. Figure 6 shows the 
cumulative survival rates for CVD death, with MMP-8, TIMP-1, and MMP-8/TIMP-1 
concentrations.  
 
MMP-8 is one of the collagenases that are able to initiate the degradation of triple-helical 
collagen and therefore it may have a clinical relevance in relation to the weakening of fibrous 
cap covering the atherosclerotic lesions. As thrombosis occurs in many cases where no 
substantial occlusions of the vessels appear, a diagnosis of possible weakening or eroding of 
the fibrous cap by serum MMP-8 could provide useful information when identifying groups 
in risk and when planning treatments.  
 
Figure 6. Cumulative survival rates for CVD death with or without increased IMT in the 
highest quartile (black line) vs. three lower quartiles (dotted line) of measured serum 
parameters. The relative risks (confidence intervals) are shown in the figure. 
†Adjusted for age, body mass index (BMI), smoking, and plasma fibrinogen concentration. 
‡Adjusted for age. 
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MMP-8 was long thought to be produced only by neutrophils, but it is expressed also in 
human ECs,  SMCs,  and  macrophages  after  stimulation  with  CD40L,  TNF-?,  or  LPS (335).  
As previously shown, MMP-8 localizes to shoulder regions of advanced atherosclerotic 
lesions, and it is expressed or elevated in patients with diagnosed CVD or plaque progression, 
but no prospective studies have been performed before (335,340,343,344). Therefore patients 
with an indication of subclinical atherosclerosis together with elevated serum MMP-8 
concentration may have an ongoing inflammatory process that eventually leads to plaque 
rupture and acute manifestation of CVD. The concept of inflammatory process behind the 
elevated MMP-8 concentrations comes from the studies showing that macrophages secrete 
MMPs (334,406). Also the increased IMT suggests an inflammatory process as the thickening 
of intima results from e.g. accumulation of lipids and increased SCM content, which both 
have shown to be present in inflammatory, atherosclerotic lesion formation (1).  
 
A recent study from our laboratory further demonstrates the relationship between MMP-8 and 
future CVD events (unpublished results). The study comprised of 140 subjects with ACS 
(acute myocardial infarction or unstable angina pectoris) that were divided into two groups 
according to the dental status in the panoramic x-rays: edentulous and periodontally healthy 
patients  or  patients  with  periodontitis.  The  follow-up  time  for  recurrent  CVD  events  (CVD  
death, MI, unstable angina, or ischemic stroke) was one year, and blood samples were 
collected at baseline, after 1 week, 3 months, and 1 year. When the whole study population or 
periodontitis patients were analysed, MMP-8 concentrations were not associated with the 
recurrent CVD events. However, in the group of edentulous and periodontally healthy 
patients, serum MMP-8 concentrations were associated with CVD events at baseline and after 
one week with RRs (95% CI, p) of 2.94 (1.038-8.313, p=0.042,) and 4.89 (1.539-15.540, 
0.007), respectively. The results therefore suggest that periodontitis increases MMP-8 
concentration and can be considered as a confounding factor. Only in periodontally healthy 
patients elevated serum MMP-8 concentration was predictive of the risk of CVD event. In our 
present study (publication IV), the only available information concerning periodontitis, was 
the serum antibody levels against major periodontal pathogens. No association, however,   
was found between those and MMP-8 concentration. 
 
According to Herman et al, in acute inflammation, MMP-8 is released from 
polymorphonuclear granulocytes, but the synthesis and release of MMP-8 from ECs, SMCs, 
and macrophages seem to require chronic inflammation with a longer exposure to 
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proinflammatory cytokines (335). These results are in good accordance with our results of 
MMP-8 being an early player in cap remodelling preceded by an inflammatory condition 
eventually leading to acute coronary symptoms. Therefore MMP-8 could well serve as a 
predictive marker of future CVD events. 
 
The importance of the sample type for MMP and TIMP measurements was addressed by 
Professor Jung (407). His data showed that from the same patients, serum samples had higher 
MMP-8 and TIMP-1 concentrations compared to plasma samples. Moreover, serum samples 
collected with a clot activator had higher MMP-8 concentrations compared to serum samples 
collected without any clot activator. The rational behind these findings is that MMP-8 and 
TIMP-1 may be released from platelets and leukocytes during the blood collection or 
coagulation. In our study, glass tubes were used, as the blood clotting in them is more 
effective  than  in  plastic  tubes  and  thus  no  clot  activators  are  needed.  We  further  tested  the  
difference between serum and plasma MMP-8 concentrations with two different methods, 
namely time-resolved immunofluorometric assay (IFMA) and ELISA (408). With both 
methods, serum MMP-8 concentrations were significantly higher than those measured from 
plasma. Notable was that there were significant positive correlations between serum and 
plasma IFMA as well as serum and plasma ELISA results thereby indicating the suitability of 
serum for these measurements. In our original publication the samples were collected in a 
uniform way from each patient and, irrespective of the origin of the MMP-8, the results 
demonstrate the association between elevated serum MMP-8 concentration and CVD event. 
Therefore the conclusions can be considered valid. 
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5. CONCLUSIONS 
 
Our data show that A. actinomycetemcomitans and C. pneumoniae induce atherosclerosis-
related alterations in serum and aorta of apoE-/- mice. Infection with A. 
actinomycetemcomitans induced inflammatory response, increased the amount of MMP-9 in 
serum and vascular tissue and cholesterol uptake into peritoneal macrophages, and reduced 
lipoprotein sizes thus transforming them more proatherogenic. Also, C. pneumoniae induced 
increased expression of inflammatory markers as well as impaired endothelial function. The 
data therefore demonstrate that infections with these pathogens can induce alterations in the 
vasculature related to early formation of atherosclerosis. 
 
In the liver, A. actinomycetemcomitans administration resulted in inflammation. Also C. 
pneumoniae induced inflammation and furthermore microvesicular appearance and fatty acid 
imbalance. The observed effects show that infections may have a more profound systemic 
influence than generally recognized. The findings of these alterations indicate that these 
organisms may adversely influence lipid metabolism, and as a consequence the course of 
cardiovascular diseases. 
 
In the population-based cohort, men with subclinical atherosclerosis, as reflected by increased 
IMT, and elevated serum MMP-8 concentration had a three-fold increased risk for CVD death 
during the 10 year follow-up. The association was independent of other CVD risk factors. As 
fatal CVD events are in many cases unexpected, our data suggest that serum MMP-8 could be 
considered as a potential new marker for risk of future CVD death. 
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